News

Atmo Biosciences reaches primary endpoints in pivotal clinical study for initial indication

Posted: 11 April 2024 Atmo Biosciences, a company commercializing the world’s first ingestible gas-sensing capsule that provides insights into gut health, is delighted to report that it has successfully reached its primary endpoints in a pivotal clinical study…

Positive preclinical data for deoxymabs in vasculitis

Posted: 11 April 2024 Patrys Limited a therapeutic antibody development company, is delighted to announce that new data from preclinical studies using PAT-DX1 and PAT-DX3 in animal models of the autoimmune disease anti-neutrophil cytoplasmic antibody (ANCA) vasculitis were…

Update on Amplia’s Accent Trial in Pancreatic Cancer

Posted: 11 April 2024 Amplia Therapeutics limited is pleased to provide an update on our Phase 1b/2a trial (the ACCENT trial) of narmafotinib in combination with standard-of-care chemotherapy gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer.…

Clarity launches $121 million fully underwritten equity raising

Posted: 11 April 2024 Clarity Pharmaceuticals (ASX:CU6) (“Clarity” or “Company”) a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce a fully…

VivaZome Therapeutics and La Trobe University to collaborate on development of extracellular vesicle therapy for treatment of stroke

Posted: 11 April 2024 VivaZome Therapeutics Pty Ltd (“VivaZome”) and La Trobe University (“La Trobe”) are pleased to announce that they will be collaborating to explore the therapeutic potential for VivaZome’s extracellular vesicles (EVs) in models of stroke…

Cartherics enters into Collaborative Research Agreement with TiCARos

Posted: 11 April 2024 Cartherics Pty Ltd (“Cartherics”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered a collaborative research agreement with TiCARos Co Ltd (“TiCARos”) to assess…

CARTHERICS EXECUTES OPTION AGREEMENT WITH THE OHIO STATE UNIVERSITY

Posted: 11 April 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP)…

INOVIQ strengthens exosome leadership with new patent application

Posted: 21 March 2024 INOVIQ Limited (ASX:IIQ or INOVIQ) is pleased to announce that it has expanded its exosome intellectual property (IP) portfolio by filing an Australian Provisional Patent Application (APPA) covering its cutting-edge EXO-ACE technology for large…

VivaZome Therapeutics and La Trobe University to collaborate on development of extracellular vesicle therapy for treatment of stroke

Posted: 21 March 2024 VivaZome Therapeutics Pty Ltd (“VivaZome”) and La Trobe University (“La Trobe”) are pleased to announce that they will be collaborating to explore the therapeutic potential for VivaZome’s extracellular vesicles (EVs) in models of stroke in the…

Cartherics executes option agreement with the Ohio State University: Tissue factor as a novel target for CAR-NK cells

Posted 20 March 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has executed an option agreement to evaluate intellectual property (IP)…

Protein discovery sparks treatment hope for aggressive cancer

Posted: 15 March 2024 Researchers have found a new way to potentially treat one of the most common forms of acute lymphoblastic leukaemia. The study, led by WEHI and the Peter MacCallum Cancer Centre, was able to kill…

DIMERIX SUCCESSFULLY PASSES EFFICACY INTERIM ANALYSIS IN ACTION3 PHASE 3 STUDY FOR FSGS KIDNEY DISEASE

Posted: 12 March 2024 Dimerix Limited (ASX: DXB, “Dimerix”), today announced that the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) was successful in the pre-specified interim analysis of the proteinuria (efficacy) endpoint…

Home

News & opinion

Member Directory

Events